AI Engines For more Details: Perplexity Kagi Labs You
Immunomodulatory Effects: Fucoidan has been shown to have immunomodulatory properties, meaning it can help regulate and support the immune system. It may enhance the activity of immune cells, such as macrophages, natural killer cells, and T cells, thereby improving the body's defense against infections and diseases.
Anti-inflammatory Activity: Fucoidan exhibits anti-inflammatory effects by inhibiting pro-inflammatory cytokines and enzymes involved in the inflammatory process. It may help reduce inflammation in various tissues and organs, potentially alleviating symptoms of inflammatory conditions such as arthritis, asthma, and inflammatory bowel disease (IBD).
Antioxidant Properties: Fucoidan possesses antioxidant properties, which help neutralize free radicals and reduce oxidative stress in the body. Antioxidants play a role in protecting cells from damage caused by reactive oxygen species (ROS) and may help prevent chronic diseases such as cardiovascular disease, cancer, and neurodegenerative disorders.
Anti-cancer Potential: Fucoidan has attracted significant attention for its potential anti-cancer properties. It may inhibit the growth and spread of cancer cells, induce apoptosis (programmed cell death), and suppress angiogenesis (the formation of new blood vessels that feed tumors). Fucoidan has been studied for its potential therapeutic effects against various types of cancer, including breast cancer, colon cancer, lung cancer, and leukemia.
Antiviral Activity: Fucoidan has been shown to have antiviral effects against a range of viruses, including herpes simplex virus (HSV), human immunodeficiency virus (HIV), influenza virus, and hepatitis C virus (HCV). It may inhibit viral attachment and entry into host cells, interfere with viral replication, and stimulate the immune response against viral infections.
Cardiovascular Health: Fucoidan may benefit cardiovascular health by reducing the risk of atherosclerosis, hypertension, and thrombosis. It may help lower cholesterol levels, inhibit platelet aggregation, and improve blood vessel function, thereby reducing the risk of heart disease and stroke.
Gastrointestinal Health: Fucoidan has been studied for its potential therapeutic effects on gastrointestinal disorders, such as gastritis, peptic ulcers, and inflammatory bowel disease (IBD). It may help reduce inflammation, promote tissue repair, and maintain the integrity of the gastrointestinal mucosa.
Skin Health: Fucoidan has moisturizing, anti-aging, and wound-healing properties that make it beneficial for skin health. It may help hydrate the skin, improve elasticity, and reduce the appearance of wrinkles and fine lines. Fucoidan-containing skincare products are used to promote skin regeneration and repair damaged skin.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | -0.2 | |
Acne | 0.9 | 0.9 | |
ADHD | 1.1 | 0.5 | 1.2 |
Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.3 | |
Allergic Rhinitis (Hay Fever) | 0.2 | 0.2 | 0 |
Allergies | 1.1 | 0.8 | 0.38 |
Allergy to milk products | 0.5 | -0.5 | |
Alopecia (Hair Loss) | 0.3 | -0.3 | |
Alzheimer's disease | 2.3 | 1.2 | 0.92 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 2.3 | -1.56 |
Ankylosing spondylitis | 0.5 | 1 | -1 |
Anorexia Nervosa | 0.3 | 0.3 | |
Asthma | 0.9 | 0.6 | 0.5 |
Atherosclerosis | 0.9 | 0.2 | 3.5 |
Atrial fibrillation | 0.8 | 1.4 | -0.75 |
Autism | 2.9 | 2.8 | 0.04 |
Bipolar Disorder | 1.1 | 0.8 | 0.38 |
Brain Trauma | 0.2 | 0.2 | |
Breast Cancer | 0.2 | 0.5 | -1.5 |
Carcinoma | 0.8 | 0.9 | -0.13 |
Celiac Disease | 0.5 | 0.3 | 0.67 |
Cerebral Palsy | 0.2 | 0.5 | -1.5 |
Chronic Fatigue Syndrome | 1.5 | 0.3 | 4 |
Chronic Kidney Disease | 1.5 | 0.7 | 1.14 |
Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 0.5 | 1.2 |
Chronic Urticaria (Hives) | 0.8 | 0.8 | |
Coagulation / Micro clot triggering bacteria | 0.5 | 0.3 | 0.67 |
Colorectal Cancer | 0.6 | 0.8 | -0.33 |
Constipation | 0.2 | 0.3 | -0.5 |
Coronary artery disease | 0.9 | 0.5 | 0.8 |
COVID-19 | 3.3 | 2.3 | 0.43 |
Crohn's Disease | 2.7 | 2.3 | 0.17 |
deep vein thrombosis | 0.3 | -0.3 | |
Depression | 3.6 | 1.1 | 2.27 |
Eczema | 0.8 | 0.3 | 1.67 |
Endometriosis | 1.5 | -1.5 | |
Epilepsy | 1.4 | 1.1 | 0.27 |
erectile dysfunction | 0.3 | -0.3 | |
Fibromyalgia | 0.5 | 0.5 | |
Functional constipation / chronic idiopathic constipation | 0.8 | 0.5 | 0.6 |
gallstone disease (gsd) | 0.5 | 0.5 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | 0 |
Generalized anxiety disorder | 0.6 | 0.6 | |
giant cell arteritis | 0.3 | -0.3 | |
Glioblastoma | 0.7 | 0.7 | |
Gout | 0.9 | 0.9 | |
Graves' disease | 0.6 | 0.4 | 0.5 |
Halitosis | 0.2 | -0.2 | |
Hashimoto's thyroiditis | 0.7 | 0.6 | 0.17 |
Hemorrhoidal disease, Hemorrhoids, Piles | 0.3 | 0.3 | |
Hidradenitis Suppurativa | 0.2 | -0.2 | |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.2 | 2 |
hyperglycemia | 0.9 | 0.3 | 2 |
Hyperlipidemia (High Blood Fats) | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 2.5 | 1.2 | 1.08 |
Hypothyroidism | 1.5 | 0.4 | 2.75 |
Hypoxia | 0.2 | 0.3 | -0.5 |
IgA nephropathy (IgAN) | 0.4 | 0.3 | 0.33 |
Inflammatory Bowel Disease | 1.7 | 0.2 | 7.5 |
Insomnia | 0.2 | 0.2 | 0 |
Intelligence | 0.2 | 0.9 | -3.5 |
Irritable Bowel Syndrome | 1.1 | 1.4 | -0.27 |
Liver Cirrhosis | 2.4 | 1.4 | 0.71 |
Long COVID | 3.2 | 2.6 | 0.23 |
Low bone mineral density | 0.9 | 0.9 | |
Lung Cancer | 0.9 | 0.9 | |
ME/CFS with IBS | 0.4 | 0.4 | |
ME/CFS without IBS | 0.2 | 0.3 | -0.5 |
Metabolic Syndrome | 3.6 | 3.2 | 0.13 |
Mood Disorders | 4.6 | 3.4 | 0.35 |
multiple chemical sensitivity [MCS] | 0.3 | -0.3 | |
Multiple Sclerosis | 1.1 | 1.1 | 0 |
Multiple system atrophy (MSA) | 0.9 | -0.9 | |
myasthenia gravis | 0.3 | 0.3 | |
Neuropathy (all types) | 0.6 | -0.6 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | 0 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.2 | 0.4 | 4.5 |
Obesity | 3.5 | 2.4 | 0.46 |
obsessive-compulsive disorder | 1.7 | 0.7 | 1.43 |
Osteoarthritis | 0.3 | -0.3 | |
Osteoporosis | 0.9 | 0.9 | |
Parkinson's Disease | 1.7 | 2.7 | -0.59 |
Polycystic ovary syndrome | 1.1 | 0.8 | 0.38 |
Postural orthostatic tachycardia syndrome | 0.6 | 0.6 | |
Premenstrual dysphoric disorder | 0.6 | 0.6 | |
primary biliary cholangitis | 0.3 | -0.3 | |
Psoriasis | 1.4 | 1.5 | -0.07 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.1 | 3 | -0.43 |
Schizophrenia | 1.8 | 2.2 | -0.22 |
scoliosis | 0.2 | 0.9 | -3.5 |
sensorineural hearing loss | 0.3 | 0.3 | 0 |
Sjögren syndrome | 0.5 | 0.2 | 1.5 |
Sleep Apnea | 1.1 | 0.6 | 0.83 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | -0.2 | |
Stress / posttraumatic stress disorder | 1.5 | 0.3 | 4 |
Systemic Lupus Erythematosus | 0.8 | 1.6 | -1 |
Tic Disorder | 0.2 | 0.2 | 0 |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 0.2 | 1.6 | -7 |
Type 2 Diabetes | 2.8 | 2.7 | 0.04 |
Ulcerative colitis | 2.6 | 0.4 | 5.5 |
Unhealthy Ageing | 1.1 | 0.8 | 0.38 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.